- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 265/30 - 1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Patent holdings for IPC class C07D 265/30
Total number of patents in this class: 856
10-year publication summary
|
64
|
54
|
47
|
54
|
64
|
56
|
47
|
61
|
58
|
19
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
19 |
| 3m Innovative Properties Company | 18406 |
17 |
| Bristol-myers Squibb Company | 5080 |
16 |
| F. Hoffmann-La Roche AG | 7958 |
16 |
| Supernus Pharmaceuticals, Inc. | 133 |
15 |
| Janssen Pharmaceutica N.V. | 3839 |
14 |
| Boehringer Ingelheim International GmbH | 4629 |
12 |
| Corsair Pharma, Inc. | 35 |
12 |
| Global Blood Therapeutics, Inc. | 180 |
12 |
| Hoffmann-La Roche Inc. | 3060 |
11 |
| BASF SE | 19740 |
10 |
| The Regents of the University of California | 18943 |
10 |
| Allergan, Inc. | 2600 |
10 |
| Astellas Pharma Inc. | 1145 |
10 |
| Merck Sharp & Dohme LLC | 3689 |
9 |
| Adverio Pharma GmbH | 44 |
7 |
| Korea University Research and Business Foundation | 2561 |
7 |
| Lundbeck Pharmaceuticals Italy S.p.A. | 28 |
7 |
| Mitsubishi Tanabe Pharma Corporation | 579 |
7 |
| Shanghai Pharmaceuticals Holding Co., Ltd. | 92 |
7 |
| Other owners | 628 |